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Introduction
Several aspects of the clinical and laboratory diagnosis of
central precocious puberty (CPP) need further evaluation.
Gonadotropin-releasing hormone (GnRH) stimulation test is
the gold standard to document premature activation of the
hypothalamic-pituitary-gonadal axis in cases with clinical
signs and symptoms of early puberty (1,2). Repeated blood
sampling at different time points (5 to 8 times) is required to
measure the levels of follicle-stimulating hormone (FSH) 
and luteinizing hormone (LH) both before and after 
administration of GnRH (3,4,5). The duration of the test is 90
to 120 minutes and 15 to 25 mL of blood is needed for 
10 to 16 measurements. The procedure is costly, time-
consuming and uncomfortable for patients. To avoid these
problems, several attempts such as measurement of basal
gonadotropin levels or subcutaneous leuprolide acetate test
with a single sample have been made (2,6,7,8,9). None of
these alternative tests have been standardized sufficiently
or proven to be equal or superior to GnRH test as yet. In
cases of precocious puberty, the GnRH test may also need
to be repeated during treatment with GnRH analogue to
assess the effectiveness of suppression and to adjust the
dose of the analogue (10,11). 
In the current study, which aimed to investigate whether
the testing procedure for diagnosis/assessment of 
CPP could be simplified without changing its validity, we
evaluated the predictive values of FSH and LH at each time
point during the GnRH test. 
ABSTRACT
Objective: Gonadotropin stimulation test is the gold standard to 
document precocious puberty. However, the test is costly, time-
consuming and uncomfortable. The aim of this study was to simplify the
intravenous gonadotropin-releasing hormone (GnRH) stimulation test in
the diagnosis of precocious puberty and in the assessment of pubertal
suppression.   
Methods: Data pertaining to 584 GnRH stimulation tests (314 tests
for diagnosis and 270 for assessment of pubertal suppression) were
analyzed. 
Results: Forty-minute post-injection samples had the greatest 
frequency of “peaking luteinizing hormone (LH)” (p<0.001) in the 
diagnostic tests when the cut-off value was taken as 5 IU/L for LH, 40th
minute sample was found to have 98% sensitivity and 100% specificity
in the diagnosis of precocious puberty, while the sensitivity and 
specificity of the 20th minute sample was 100% in the assessment of
pubertal suppression. 
Conclusion: LH level at the 40th minute post-injection in the diagnosis
of central precocious puberty and at the 20thminute post-injection in the
assessment of pubertal suppression is highly sensitive and specific. 
A single sample at these time points can be used in the diagnosis of
early puberty and in the assessment of pubertal suppression.  
Key words: Central precocious puberty, follicle stimulating hormone, 
luteinizing hormone, GnRH analogue, hypotalamo-pituitary-gonadal axis,
GnRH stimulation test
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Diagnostic Group
This group comprised 263 girls presenting with early
pubertal signs. The age of onset as well as the tempo of
puberty were extracted from patient records. Physical
examination included body weight, height, and estimation
of breast and pubic hair development according to the
Tanner classification. Bone age was assessed using the
Greulich-Pyle method (12).
Indications for GnRH stimulation test were: 
1. Onset of pubertal signs and growth acceleration
before the age of 8 years.
2. Accelerated pubertal progression associated with
advanced bone age after the age of 8 years.
Group Under Treatment with GnRH Analogue
Patients whose diagnosis of CPP was confirmed by
basal ort ic GnRH stimulated peak LH were treated with
GnRH analogue (leuprolide acetate) to suppress puberty.
These patients constituted this group. All these patients
were initially treated with an intramuscular injection 
of leuprolide acetate 3.75 mg every 28 days. In order to
ascertain the adequacy of suppression of puberty in these
patients, a repeat GnRH test was performed in the course
of their treatment (re-test). Re-tests were done 3 weeks
after the third dose of the GnRH analogue. In patients with
inadequate suppression of puberty, the dose of the GnRH
analogue was doubled (see below). 
The GnRH test was performed at 800-830 a.m. An 
intravenous (IV) cannula was inserted and blood samples
were collected for basal FSH and LH. Following administration
of a standard dose of 100 μg GnRH (Gonadorelin acetate,
Ferring®), blood samples for FSH and LH were obtained at
the 20th, 40th, 60th and 90th minutes. FSH and LH were
measured using chemiluminescent microparticle
immunoassay (ARCHITECH System, Abbott Laboratory
Diagnostics, USA). The minimum detectable concentration
was 0.07 IU/L for both FSH and LH. A cut-off value of 
stimulated LH of greater than or equal to 5 IU/L was 
considered diagnostic for pubertal response in patients 
with pubertal signs (13). In the course of GnRH analogue
therapy, a cut-off value of less than 2 IU/L for LH in IV GnRH
stimulation test was deemed to demonstrate adequate
suppression of puberty (10).
Statistical Analysis
Stastistical analysis was carried out using Statistical
Package for the Social Sciences, version 15.0 for Windows
(SPSS Inc., Chicago, IL). The data are given as means±SD.
Frequencies were compared using the χ2-test. The
Friedman test was used for repeated measures, Wilcoxon
rank test and Mann-Whitney U test were used to compare
means. A p value of less than 0.05 was considered to be
statistically significant.
The diagnostic values of FSH, LH as well as LH/FSH
ratio at different time points during GnRH test were 
evaluated using receiver operating characteristic (ROC)
analysis. 
Results
Diagnostic Group
Three hundred and fourteen tests for the diagnosis 
of CPP were performed in 263 girls with signs of early
puberty. The mean values for chronological age, height age
and bone age were 7.9±1.5, 8.8±1.8 and 9.5±1.9 years,
respectively. The mean body weight was 32.2±8.2 kg
Pubertal development was compatible with Tanner stage 
2 in 62.5%, and with stage 3 in 37.5% of patients.  
The mean LH level at the 40th minute of the test
(7.9±9.9 IU/L) was higher than the mean values at all other
time points (p<0.001). The peak LH level coincided with the
40th minute sample in 71% of patients, and this occurrence
was significantly more frequent at that compared to the
other time points (p=0.03) (Table 1). In 152 out of 314
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Figure 1. The ROC curves of LH at different time points of the test
(20th, 40th, 60th and 90th minutes). 
LH: luteinizing hormone
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40th minute 0.999 98.0 100.0
60th minute 0.989 96.1 95.7
90th minute 0.987 94.1 96.3(48.4%) tests, the peak LH was above the cut-off, and the
test was diagnostic for CPP. Among these patients, in
149/152 (98%) of the tests, the 40th minute sample was
diagnostic for CPP with an LH level above 5 IU/L, even if it
was not the peak. Also in all prepubertal patients 
(162 tests), the 40th minute sample LH was below 5 IU/mL,
even if LH did not peak at the 40th minute.
The mean FSH level at the 60th minute of the test was
12.1±11.3 IU/L, a value higher than those at all other time
points (p<0.001). Additionally, at the 60th minute of the
tests, the highest frequency of peak FSH (42%) was
obtained (Table 1). 
Figure 1 presents the ROC curves of LH at different
time points of the test. The ROC curve for LH at the 40th
minute was the most diagnostic one since it had the 
greatest area under the curve (AUC). 5 IU/L was considered
as cut-off for LH in the diagnosis of CPP, and the ROC
curves showed that a level of 4.93 IU/L at the 40th minute
was the most sensitive (98%) and specific (100%) cut-off
for LH in the diagnosis.      
The mean basal LH level in the group with pubertal
response to the GnRH test was higher than that of the 
prepubertal group (1.05 and 0.22 mIU/L, respectively,
p<0.0001). However, analysis of the diagnostic value 
of basal LH using ROC revealed that sensitivity and 
specificity of basal LH were both low (69.1% and 79.6%,
respectively) in the diagnosis of CPP (Figure 2). Also, basal
LH level in 13 of the 152 (8.5%) patients with a pubertal
response to GnRH were below the lowest detectable level
(<0.07 IU/L). When we considered basal LH ≥1 IU/L as the
cut-off level for diagnosis of CPP, the positive predictive
value of basal LH was 96.4% and the negative predictive
value was 61.8%.                     
Evaluation of LH/FSH ratio demonstrated no statistically
significant difference in LH/FSH ratios between prepubertal
and pubertal response groups both in the basal 
state (p=0.328) and in the peaks (p=0.718). Sensitivity and
specificity of basal and peak LH levels are shown in Figure 3.
Evaluation of the diagnostic value of FSH using ROC
analysis revealed that none of the time points, or any 
levels of FSH were sensitive or specific enough to allow a
diagnosis of CPP.
Group Under Treatment with GnRH Analogue
Two hundred seventy tests were performed to assess
pubertal suppression. The results are shown in Table 2. The
mean LH level (1.2IU/L±0.9) was higher at the 20th minute
of the test in comparison to the other time points
(p<0.001). Also, peak LH was noted at the 20th minute in
249 of the 270 patients (92.2%). Two hundred and 
thirty-four patients (86.7%) were found to have a 
suppressed LH response to GnRH (peak LH < 2 IU/L). The
peak LH level in 215 out of 234 patients (91.8%) with 
suppressed GnRH test was at the 20th minute, whereas in
14
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Figure 2. The ROC curve of basal LH  levels in the diagnosis of CPP
LH: luteinizing hormone, CPP: central precocious puberty
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Figure 3. ROC curve of LH level at different time points of 
GnRH tests performed for assessment of pubertal suppression
LH: luteinizing hormone, GnRH: gonadotropin-releasing hormonethe remaining 19 patients (8.2%), the peak LH level was at
the 40th minute.  In 36 (13.3%) patients, GnRH-stimulated
LH peak was ≥2 IU/L, showing inadequate suppression, and
the dose of the GnRH analogue had to be increased. 
The 20th minute LH levels were ≥2 IU/L in all patients with
inadequate suppression. Also, 20th minute LH levels 
were <2 IU/L in all 234 patients (100%) with adequate 
suppression in response to GnRH test. In addition, the AUC
in ROC analysis was greatest at the 20th minute, 
with 100% sensitivity and specificity using a cut-off of 1.98
IU/L for LH. 
Evaluation of basal LH values for assessment of 
pubertal suppression using ROC analysis revealed that
basal LH showed pubertal suppression with 83.3% 
sensitivity and 67.9%  specificity (AUC was 0.813 and LH
cut-off value considered for pubertal suppression was 0.3
IU/L). According to this cut-off, the negative predictive value
and the positive predictive value of basal LH were found to
be 96.4% and 28.5%, respectively. 
Discussion
GnRH test is the gold standard for the diagnosis of CPP.
However, the test is time-consuming, costly and 
uncomfortable for the patients. In the current study, in an
attempt to simplify the GnRH test, we analyzed the LH
response to the GnRH test performed to diagnose 
precocious puberty and also to assess the adequacy of 
suppression with a GnRH analogue.  Different cut-off 
values of peak LH are used in the diagnosis of CPP in
patients with early pubertal signs, and also in the 
assessment of pubertal suppression in patients under 
treatment with a GnRH analogue. Cut-off values also differ
depending on the assay used to measure LH
15
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Table 1. FSH, LH levels and frequency of peak LH and FSH at each time point during the GnRH stimulation test
Basal 20th minute 40th minute 60th minute 90th minute
LH level (IU/L) (mean±SD) 0.51±0.8 7.3±10.0a 7.9±9.9b 6.8±8.2a 5.1±6.0
Frequency of peak LH (%) 0 60 223 29 2
(0) (19.1) (71.0) (9.2) (0.6)
Cross-sectional frequency of  LH ≥5 IU/L(%) 0 125 149 127 92
(0) (82.2) (98.0) (83.6) (60.5)
Cumulative  frequency of  LH ≥5 IU/L(%) 0 125 151 152 152
(0) (82.2) (99.3) (100) (100)
FSH level (IU/mL) (mean±SD) 2.85±2.6 8.2±6.2 11.1±9.8 12.1±11.3c 11.9±11.3
Frequency of peak FSH (%) 0          7 55 132 120
(0) (2.2) (17.5) (42) (38.2)
aMean LH levels at 20th and 60th minutes were similar (p=0.99)
b Mean LH at 40th and mean FSH at 60th minutes were higher than the other time points (p<0.001)
GnRH: gonadotropin-releasing hormone ,  LH: luteinizing hormone, FSH: follicle-stimulating hormone
Table 2. FSH, LH levels and frequency of peak LH at each time point during the GnRH stimulation test in patients under treatment with GnRH analogue
Basal 20th minute 40th minute 60th minute 90th minute
LH level (IU/L) (mean±SD) 0.29±0.2 1.2±0.9 0.98±0.7 0.78±0.6 0.67±0.9
Frequency  of peak LH (%) 0          249 21 0 0
(0) (92.2) (7.8) (0) (0)
Frequency of LH ≥2 IU/L (%)  0          36 18 11 5
(0) (100) (50.0) (30.5) (13.9)
FSH level (IU/L) (mean±SD) 1.15±0.7 1.89±1.3 1.93±1.48 1.83±1.46 1.66±1.27
Frequency  of peak FSH (%) 0             87 80 22 3
(0) (45.3) (41.7) (11.5) (1.6)
GnRH: gonadotropin-releasing hormone,   LH: luteinizing hormone,  FSH: follicle-stimulating hormone(5,13,14,15,16) In our clinic, LH is measured using ICMA,
and LH ≥5 IU/L is considered to be diagnostic for CPP (13),
whereas LH should be below 2 IU/L in order to consider a
patient with CPP under GnRH analogue treatment as 
adequately suppressed (10). 
Comparison of peak LH levels at different time points
during the GnRH test performed for the diagnosis of CPP
showed that the mean LH value at the 40th minute of the
test was greater than those at other time points. Also, a
greater number of LH peaks coincided with the 40th minute
samples. These findings suggest that a single sample
obtained at the 40th minute of the GnRH test may be used
in the diagnosis of CPP with high sensitivity (98%) and
specificity (100%).  
Previous studies reported LH to peak between 30 and
60 minutes of the GnRH test (5,13,14,17,18,19,20), but
none of these studies aimed to simplify the standard IV
GnRH test, except the study by Cavallo et al (5). These
authors suggested that a single LH determination at the
30th minute of the test was diagnostic. However, their
study included only 55 diagnostic tests in 51 patients. To
our best knowledge, the current study comprises the
largest homogeneous population in this regard. 
Some authors suggest that LH/FSH ratio may also be
valuable in the diagnosis of CPP (3,18,21). Jiang et al (18)
reported that LH/FSH>0.9 at the 15th minute of the 
test might be diagnostic, but with lower sensitivity and
specificity (80% and 90%, respectively). In another study,
the peak LH/FSH >1 was found to have the highest positive
predictive value (93.8%) (22). In the current study, both
basal and stimulated LH/FSH ratios had lower sensitivity
and specificity in comparison to the peak LH level in the
diagnosis of CPP. Similarly, FSH levels, both basal and
peak, had poor diagnostic value. Data from other studies
also indicate that FSH has a poor diagnostic value in CPP (5).
In the last decade, the use of third-generation assays in
the measurement of gonadotropin (FSH and LH) levels
enabled clinicians to apply basal LH levels in the diagnosis
of CPP (6,7). Neely et al (6) reported that a basal LH >0.1
IU/L was diagnostic for CPP with 94% sensitivity and 88%
specificity. They also showed that a cut-off value >0.3 IU/L
increased the specificity to 100% even though the 
sensitivity was reduced. Recently, Houk et al (7) suggested
that using a basal LH >0.83 IU/L as the cut-off value 
yielded high sensitivity (93%) and specificity (100%) for the
diagnosis of CPP. However, their study included a limited
number of patients and the pubertal stage of the patients
was not reported. According to our ROC curve analysis,
basal LH > 0.3 IU/L had the highest sensitivitiy (65.1%) and
specificity (86.4%). However, these values were lower 
than those reported in the study by Houk et al (7). When we
considered basal LH>0.83 as the cut-off value, the sensitivity
was found very low (34.2%), while the specificity was
96.3%. Furthermore, it was observed that 13 of the 
152 patients (8.5%) diagnosed with CPP in the IV GnRH
stimulation test had undetectable basal LH levels. When LH
≥1 IU/L was considered as the cut-off for the diagnosis of
CPP, the positive predictive value of basal LH was 
found adequate to confirm the diagnosis of CPP without
performing an IV GnRH stimulation test. Therefore, we do
not suggest using basal LH as a single diagnostic criteria for
CPP, except for LH ≥1 IU/L, which displayed a high positive
predictive value (96.4%).
Analysis of pubertal suppression in 270 patients under
treatment with a GnRH analogue for CPP revealed that LH
level at the 20th minute of the test was 100% sensitive 
and specific to determine adequacy of suppression.
Previous studies analyzed data regarding both diagnostic
and follow-up GnRH tests; however, the specific question
about the value of a single LH level to show the adequacy
of pubertal suppression was not addressed (13). Cavallo et
al (5) analyzed 39 tests in the course of treatment, but, their
analysis was inconclusive owing to the small number of
cases who were inadequately supressed.  Furthermore,
because of its low sensitivity and specificity, we do not 
recommend basal LH value as a single criterion in the
assessment of pubertal supression, with the exception of
LH <0.3 IU/L, which displayed a high negative predictive
value (96.4%). Therefore, basal LH can be used as a 
screening test to show pubertal suppression, and in case of
LH ≥0.3, an IV GnRH stimulation test should be performed
for dose adjustment. This cut-off value was previously 
presented as a criterion to differentiate prepubertal from
pubertal patients  (6,13).
Separate analysis of the GnRH test in the diagnostic and
treatment groups revealed an interesting finding.
Gonadotropin levels peaked more rapidly in patients under
treatment in comparison to those who were assessed 
for suppression. FSH levels also peaked more rapidly in the
re-test group. 
In conclusion, a single sample of LH obtained at the 40th
minute of the GnRH test may be adequate for the 
diagnosis of CPP if a cut-off value of 5 IU/L is applied. Also,
our findings indicate that a single measurement of LH at 
the 20th minute of the GnRH test using a cut-off value of 2
IU/L is as valid as the standard test to evaluate pubertal 
suppression in patients under treatment with a GnRH 
analogue. 
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